BHP Faces Major Port Hedland Strike as Labor Talks Stall Ahead of Production Report 
ASML Raises 2026 Outlook as AI Chip Demand Lifts Q2 Earnings 
Stripe, Advent Offer Over $53 Billion to Acquire PayPal in Major Fintech Deal 
Volkswagen Launches €28,000 ID. Cross EV as Europe’s Electric Vehicle Demand Accelerates 
DeepSeek Eyes China IPO as AI Startup Seeks $71 Billion Valuation in New Funding Round 
Paramount-Warner Bros. Discovery Merger Faces Lawsuit From 12 States 
Apple Intelligence China Approval Lifts Alibaba and Baidu Shares 
Arm Stock Falls After HSBC Downgrade, Citing Limited Near-Term AI Upside 
SpaceX Stock Falls Below IPO Price as Investors Weigh Losses and Lockup Expiry 
United Airlines Beats Q2 Earnings, Raises 2026 Profit Outlook Despite Higher Fuel Costs 
Hyundai Takes Full Control of Boston Dynamics to Accelerate Humanoid Robot and AI Strategy 
Taiwan Mangoes Head to Europe as Premium Fruit Exports Expand 
Rio Tinto Reports Strong Q2 Iron Ore Sales, Maintains 2026 Production Outlook 
Nvidia Partners With Fanuc and Yaskawa to Accelerate AI Robotics in Japan 
SK Hynix Stock Soars as AI Memory Demand Outlook Fuels Chip Rally 
UBS Boosts China Tech Bets, Adds Kuaishou and Meituan to Focus List 
xAI Sues Man for Allegedly Using Grok to Generate AI Child Abuse Deepfakes 
Novo Nordisk (NYSE:NVO) forecasted slower sales growth for 2025, reflecting an expected moderation in demand for its blockbuster obesity drug, Wegovy. The Danish pharmaceutical giant projects local currency sales growth between 16% and 24%, down from 26% in 2024 but aligning with analysts' expectations of around 20%.
Novo Nordisk faces increasing competition from Eli Lilly (NYSE:LLY), a key rival in the weight-loss drug market. Despite this, the company reported strong fourth-quarter results, with operating profit surging 37% to 36.7 billion Danish crowns ($5.12 billion), surpassing analysts' estimates of 33.6 billion. For 2025, the company expects operating profit growth between 19% and 27%, compared to last year's 26%.
Wegovy sales more than doubled in Q4, reaching 19.9 billion crowns, up from 9.6 billion a year earlier and exceeding the 17.3 billion recorded in Q3. The sustained demand underscores the drug’s strong market position, although future growth is expected to decelerate.
As the weight-loss drug market evolves, Novo Nordisk continues to navigate supply constraints and rising competition. Investors remain focused on the company’s long-term outlook as it balances expansion efforts with growing market challenges.
